Lutetium-177 PSMA-617 improves symptoms related to bone metastasis in prostate cancer - Urology Times
In this interview, Brian D. Gonzalez, PhD, shares results that were presented at the 2022 ASCO Genitourinary Cancers Symposium from the study, "Improvements in symptoms related to bone metastasis in recipients of Lutetium-177 PSMA-617 for prostate cancer."
Prostate-specific membrane antigen (PSMA) radioligand therapy for prostate cancer has demonstrated many promising results in previous trials, such as improved progression-free survival, overall survi… [+3543 chars]
Read More
Other Stories in Health
- Dosa saree, Idli shirt and a pani puri watch? AI turns desi food into fashion
- Where and why men die younger: global data breaks it down
- 8 Best Foldable Rowing Machines, According to Editors and Certified Trainers
- Strawberry Lemon Cream Crepes {Grain-Free Options Included}
- What predicts belief in the afterlife? A massive global study has answers
- Getting active in midlife may boost brain resilience to Alzheimer’s
- May 2025 Cooking Challenge
- May 2025 Cooking Challenge
- TDP-43 dysfunction in brain blood vessels may drive Alzheimer's and ALS progression
.png)
